Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
Early terminated RCT with 81 hospitalized patients, 38 treated with convalescent plasma, showing lower progression with treatment.
NCT04345523 (history).
risk of death, 88.3% lower, RR 0.12, p = 0.12, treatment 0 of 38 (0.0%), control 4 of 43 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29.
|
risk of progression, 93.0% lower, RR 0.07, p = 0.01, treatment 0 of 38 (0.0%), control 7 of 43 (16.3%), NNT 6.1, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29, progression to categories 5-7.
|
risk of progression, 91.9% lower, RR 0.08, p = 0.03, treatment 0 of 38 (0.0%), control 6 of 43 (14.0%), NNT 7.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 15, progression to categories 5-7, primary outcome.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Avendaño-Solà et al., 29 Sep 2020, Randomized Controlled Trial, Spain, peer-reviewed, 36 authors, average treatment delay 8.0 days, trial
NCT04345523 (history).
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.08.26.20182444; this version posted September 29, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Original Article
Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
Authors:
C Avendaño-Solà1, A Ramos-Martínez2, E Muñez-Rubio2, B Ruiz-Antorán1, R Malo de Molina3, F Torres4,
A Fernández-Cruz2, A Callejas-Díaz2, J Calderón2, C Payares-Herrera1, I Salcedo1, I Romera5, J LoraTamayo6, M Mancheño-Losa6, ML Paciello7, C Villegas7, V Estrada8, I Saez-Serrano9, ML Porras-Leal10,
MC Jarilla-Fernández11, JR Paño-Pardo12, JA Moreno-Chulilla13, I Arrieta-Aldea14, A Bosch15, M
Belhassen-Garcia16, O López-Villar17, A Ramos-Garrido18, L Blanco19, ME Madrigal-Sánchez20, E
Contreras21, E Muñiz-Díaz22, JM Domingo-Morera23, I Casas-Flecha24, M Pérez-Olmeda25, Javier GarciaPérez26, J Alcamí26, JL Bueno5 and RF Duarte 5 for the ConPlas-19 Study Group*
*Complete list of the ConPlas-19 study group provided in the Supplementary Appendix
Affiliations:
1. Clinical Pharmacology Department. Hospital Universitario Puerta de Hierro Majadahonda, Instituto de
Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana, Madrid, Spain. SCReN Clinical
Trials Platform.
2. Infectious Diseases Unit, Department of Internal Medicine. Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain.
3. Respiratory Medicine Service. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
4. Clinical Pharmacology Department, Hospital Clinic Barcelona, Barcelona, Spain. Biostatistics Unit,
Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
5. Department of Hematology. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
6. Department of Internal Medicine. Hospital Universitario 12 de Octubre. Instituto de Investigación
"i+12" Hospital 12 de Octubre, Madrid,Spain.
7. Department of Hematology. Hospital Universitario 12 de Octubre,Madrid, Spain
8. Infectious Diseases Unit, Department of Internal Medicine.Hospital Universitario Clinico San Carlos,
Madrid, Spain.
9. Hematology Service. Hospital Universitario Clinico San Carlos. Madrid, Spain.
10. Infectious Diseases Unit, Department of Internal Medicine, Hospital General Universitario de Ciudad
Real, Ciudad Real, Spain.
11. Hematology and Hemotherapy Service, Hospital General Universitario de Ciudad Real, Ciudad Real,
Spain.
12. Division of Infectious Diseases. Hospital Clínico Universitario Zaragoza-IIS Aragón, Spain
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1
medRxiv preprint doi: https://doi.org/10.1101/2020.08.26.20182444; this version posted September 29, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
13. Servicio de Hematología Hospital Clínico Universitario Lozano Blesa, Zaragoza,Spain
14. Infectious Diseases Department, Hospital del Mar, Barcelona, Spain.
15. Blood Transfusion Service. Hospital del Mar. Consorci Mar Parc de Salut. Banc de Sang i Teixits.
Barcelona. Spain
16. Internal Medicine..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit